Sugi Predict

Sugi Predict / Targets / GRIK4

GRIK4

Glutamate receptor ionotropic, kainate 4 (Glu · Q16099 · GRIK4 on Sugi Atlas →

3,103 patent compounds predicted against GRIK4, 1,907 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7479472 SCHEMBL7479472 0.87 14/20
SCHEMBL7479864 SCHEMBL7479864 0.85 14/20
SCHEMBL7479847 SCHEMBL7479847 0.68 13/20
SCHEMBL6598030 SCHEMBL6598030 0.70 12/20
SCHEMBL7480775 SCHEMBL7480775 0.73 11/20
SCHEMBL6593784 SCHEMBL6593784 0.72 11/20
SCHEMBL6602262 SCHEMBL6602262 0.65 11/20
SCHEMBL6604215 SCHEMBL6604215 0.58 11/20
SCHEMBL7488054 SCHEMBL7488054 0.55 11/20
SCHEMBL6604533 SCHEMBL6604533 0.54 11/20
SCHEMBL6605459 SCHEMBL6605459 0.49 11/20
SCHEMBL6602512 SCHEMBL6602512 0.49 11/20
SCHEMBL6602507 SCHEMBL6602507 0.48 11/20
SCHEMBL6608104 SCHEMBL6608104 0.71 10/20
SCHEMBL6607049 SCHEMBL6607049 0.70 10/20
SCHEMBL6601674 SCHEMBL6601674 0.70 10/20
SCHEMBL6602498 SCHEMBL6602498 0.62 10/20
SCHEMBL6604907 SCHEMBL6604907 0.61 10/20
SCHEMBL6606394 SCHEMBL6606394 0.61 10/20
SCHEMBL7480169 SCHEMBL7480169 0.60 10/20

Clinical trials — most relevant to GRIK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Memantine for Refractory OCD Patients PHASE3UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease PHASE3COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD PHASE2RECRUITING
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia PHASE1/PHASE2COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response PHASE1RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression PHASE1RECRUITING
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
(GluEsk) Glutamate and Esketamine nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Methadone in Adults Undergoing Cardiac Surgery nanCOMPLETED
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis nanRECRUITING
Mechanisms of Human Plasticity in the Human System nanCOMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction? nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIK4 binder may also engage these)

ProteinNameSimilarity
Q01812 — 1.000 Q01812 →
Q8BMF5 — 1.000 Q8BMF5 →
Q5IS46 — 1.000 Q5IS46 →
B1AS29 — 0.998 B1AS29 →
P42264 — 0.998 P42264 →
Q61626 — 0.997 Q61626 →
Q60934 — 0.997 Q60934 →
Q63273 — 0.996 Q63273 →
GRIK5 Glutamate receptor ionotropic, kainate 5 0.996 landscape →
Q38PU2 — 0.995 Q38PU2 →
P42260 — 0.993 P42260 →
GRIK3 Glutamate receptor ionotropic, kainate 3 0.992 landscape →
P26591 — 0.992 P26591 →
Q91755 — 0.991 Q91755 →
P34299 — 0.991 P34299 →
Q90218 — 0.991 Q90218 →
Q38PU3 — 0.990 Q38PU3 →
GRIK2 Glutamate receptor ionotropic, kainate 2 0.990 landscape →
P39087 — 0.990 P39087 →
P19439 — 0.989 P19439 →
A0A2R8QF68 — 0.989 A0A2R8QF68 →
GRIK1 Glutamate receptor ionotropic, kainate 1 0.988 landscape →
Q7XP59 — 0.987 Q7XP59 →
Q38PU4 — 0.987 Q38PU4 →
Q91756 — 0.987 Q91756 →
Q80T41 — 0.987 Q80T41 →
Q9Z2W8 — 0.987 Q9Z2W8 →
G5ECB2 — 0.987 G5ECB2 →
Q21415 — 0.987 Q21415 →
Q9SW97 — 0.986 Q9SW97 →